Kong Yanan, Lyu Ning, Wu Jiali, Tang Hailin, Xie Xinhua, Yang Lu, Li Xing, Wei Weidong, Xie Xiaoming
Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China; Department of Minimally Invasive Intervention, Sun Yat-sen University Cancer Center, Guangzhou, China.
J Cancer. 2018 Sep 8;9(20):3728-3735. doi: 10.7150/jca.28032. eCollection 2018.
CD44 and ALDH1 have been recognized as the most widely used markers to identify breast cancer stem cells (BCSCs). However, limited to tissue sample and rare population, BCSCs have always been not easily detected. We aimed to measure CD44 and ALDH1A1 (major contributor to ALDH1 activity) levels in serum and explore the prognostic value in primary breast cancer patients. This study included 140 primary breast cancer patients with stage I-III. Serum samples were collected before surgery and stored at -80 degrees. CD44 and ALDH1A1 were measured by chemiluminescent assay. High serum CD44 levels (≥ 417.4 ng/mL) were correlated with postmenopausal status ( = 0.006), estrogen receptor negativity ( = 0.025), progesterone receptor negativity ( = 0.002) and adjuvant chemotherapy ( = 0.003). The mean serum CD44 levels of luminal group (406.4 ± 68.3 ng/mL) were significantly lower than triple negative group (506.8 ± 175.5 ng/mL) ( < 0.001). There was no correlation between serum ALDH1A1 levels and molecular subtypes. Multivariate analysis revealed that high serum CD44 level (≥ 417.4 ng/mL), was an independent factor for PFS ( = 0.019) and OS ( = 0.008). However, serum ALDH1A1 has no impact on either PFS ( = 0.613) or OS ( = 0.441). Serum CD44 was an independent prognostic indicator in primary breast cancer. However, serum ALDH1A1 has no impact on survivals and might not be an appropriate candidate to predict prognosis for breast cancer.
CD44和ALDH1已被公认为是鉴定乳腺癌干细胞（BCSCs）最广泛使用的标志物。然而，由于受组织样本和罕见群体的限制，BCSCs一直不易被检测到。我们旨在测定血清中CD44和ALDH1A1（ALDH1活性的主要贡献者）水平，并探讨其在原发性乳腺癌患者中的预后价值。本研究纳入了140例I-III期原发性乳腺癌患者。术前采集血清样本并储存在-80度。采用化学发光法测定CD44和ALDH1A1。血清CD44高水平（≥417.4 ng/mL）与绝经后状态（P = 0.006）、雌激素受体阴性（P = 0.025）、孕激素受体阴性（P = 0.002）及辅助化疗（P = 0.003）相关。腔面型组的血清CD44平均水平（406.4±68.3 ng/mL）显著低于三阴性组（506.8±175.5 ng/mL）（P<0.001）。血清ALDH1A1水平与分子亚型之间无相关性。多变量分析显示，血清CD44高水平（≥417.4 ng/mL）是无进展生存期（P = 0.019）和总生存期（P = 0.008）的独立因素。然而，血清ALDH1A1对无进展生存期（P = 0.613）或总生存期（P = 0.441）均无影响。血清CD44是原发性乳腺癌的独立预后指标。然而，血清ALDH1A1对生存率无影响，可能不是预测乳腺癌预后的合适指标。
